Axsome Therapeutics AXSM Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's contingent consideration liability (non-current)?
- Axsome Therapeutics (AXSM) reported contingent consideration liability (non-current) of $73.73M in Q1 2026.
- How has Axsome Therapeutics's contingent consideration liability (non-current) changed year-over-year?
- Axsome Therapeutics's contingent consideration liability (non-current) decreased by 18.6% year-over-year, from $90.59M to $73.73M.
- What is the long-term trend for Axsome Therapeutics's contingent consideration liability (non-current)?
- Over 3 years (2022 to 2025), Axsome Therapeutics's contingent consideration liability (non-current) has grown at a 35.6% compound annual growth rate (CAGR), from $31.1M to $77.54M.
- What does contingent consideration liability (non-current) mean?
- Future payments owed for past acquisitions if certain goals are met.
- How do you interpret contingent consideration liability (non-current)?
- Changes reflect management's updated probability assessments of achieving milestones, impacting future cash outflows.
- How does contingent consideration liability (non-current) compare across companies?
- Specific to companies that grow through M&A and milestone-based deal structures.